Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 1.00% as of January 14, 2026, with Tianzhihang leading the gain at 18.97% and Rongchang Biopharmaceuticals experiencing the largest drop at 9.83% [1] - Eight departments jointly issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'," emphasizing the promotion of intelligent equipment iteration and supporting AI applications in high-end medical equipment and telemedicine [1] - Nvidia and Eli Lilly announced the establishment of an AI joint laboratory, planning to invest up to $1 billion over the next five years to accelerate drug development, indicating increased investment from leading overseas companies in domestic related fields [1] Group 2 - CITIC Securities reported that the medical AI sector is expected to accelerate the restructuring of the trillion-yuan pharmaceutical market, with a fundamental change in the payment logic for AI medical services anticipated in 2026 [2] - The top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 48.85% as of December 31, 2025, including companies like United Imaging Healthcare and BeiGene [2] Group 3 - The Jiashi Sci-Tech Medical ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, providing an opportunity for investors to easily access the biopharmaceutical sector [3]

1. Report Industry Investment Ratings - Stock Index Futures: Oscillating [1] - Treasury Bond Futures: Relatively Strong [2] 2. Core Views of the Report - The A-share market adjusted with oscillations throughout the day, with the ChiNext Index dropping nearly 2%. AI-related concepts and some sectors like oil and gas and power grid equipment showed strength, while the commercial spaceflight concept declined. The trading volume reached 3.7 trillion yuan, setting a new record. The rise of the A-share index at the beginning of 2026 was driven by global technological development, the Fed's potential interest rate cuts, and the weakening dollar. The tense global geopolitical situation led to a short-term surge in rare metals. With the index at a high level and heavy trading volume, caution is advised when chasing high prices, and it is recommended to wait and see [1]. - On Tuesday, treasury bond futures closed with gains in some contracts. The central bank conducted reverse repurchase operations, resulting in a net capital withdrawal. The short-term sufficient liquidity supports the bond market, but factors such as economic stability, rising inflation, and cautiousness towards interest rate cuts pose certain constraints. The bond market is expected to remain in a range-bound oscillation pattern in the short term [2]. 3. Summary by Relevant Catalogs 3.1 Research Views - **Stock Index Futures**: The market adjusted with oscillations, with the ChiNext Index down nearly 2%. AI medical, AI pharmaceutical, AI marketing, oil and gas, and power grid equipment sectors performed well, while the commercial spaceflight concept retreated. The trading volume reached 3.7 trillion yuan, a new record. The index rise at the beginning of 2026 was driven by global technological development, the Fed's potential interest rate cuts, and the weakening dollar. The tense geopolitical situation led to a short - term surge in rare metals. With the index at a high level and heavy trading volume, caution is needed when chasing high prices, and it is advisable to wait and see [1]. - **Treasury Bond Futures**: On Tuesday, the 30 - year, 10 - year, and 5 - year treasury bond futures contracts closed higher, while the 2 - year contract remained stable. The central bank conducted 3586 billion yuan of 7 - day reverse repurchase operations, resulting in a net capital withdrawal of 2576 billion yuan. The short - term sufficient liquidity supports the bond market, but economic stability, rising inflation, and cautiousness towards interest rate cuts pose constraints. The bond market is expected to remain range - bound in the short term [2]. 3.2 Price Changes on the Day - **Stock Index Futures**: On January 13, 2026, IH decreased by 0.08%, IF by 0.32%, IC by 1.28%, and IM by 1.82% compared to the previous day [4]. - **Stock Indexes**: The Shanghai Composite 50 Index decreased by 0.34%, the CSI 300 Index by 0.60%, the CSI 500 Index by 1.28%, and the CSI 1000 Index by 1.84% [4]. - **Treasury Bond Futures**: TS decreased by 0.01%, TF remained unchanged, T increased slightly by 0.00%, and TL increased by 0.13% [4]. 3.3 Market News - The market adjusted with oscillations throughout the day, with the ChiNext Index down nearly 2%. AI - related concepts and some sectors like oil and gas and power grid equipment showed strength, while the commercial spaceflight concept declined. The trading volume reached 3.7 trillion yuan, a new record. The Shanghai Composite Index closed down 0.64%, the Shenzhen Component Index down 1.37%, and the ChiNext Index down 1.96% [5]. - AI medical, AI pharmaceutical, AI marketing, and oil and gas sectors led the gains, while commercial spaceflight, controlled nuclear fusion, quantum technology, and optical communication sectors led the losses [5]. - There were 1520 rising stocks, 74 daily limit stocks, 3547 falling stocks, 56 daily limit down stocks, and 58 stocks with broken daily limits, with a broken - limit rate of 47% [5]. 3.4 Chart Analysis - **Stock Index Futures**: The report presents the historical price trends and basis trends of IH, IF, IC, and IM contracts [7][9][11]. - **Treasury Bond Futures**: The report shows the historical price trends, basis trends, inter - period spread trends, cross - variety spread trends, and capital interest rate trends of treasury bond futures contracts [14][16][19][22]. - **Exchange Rates**: The report displays the historical trends of the central parity rate of the US dollar against the RMB, the euro against the RMB, forward exchange rates, the US dollar index, and exchange rates between major currencies [24][25][26][28][30].

Group 1 - The core viewpoint of the news highlights the strong performance of the innovative drug ETF Tianhong (517380) and the medical device ETF (159873), both reaching new highs in terms of scale and shares [1][2] - As of January 13, the innovative drug ETF Tianhong (517380) has a scale of 1.807 billion yuan and 2.162 billion shares, marking a record high since its inception [1] - The innovative drug ETF has seen a net inflow of 264 million yuan over the past six days, indicating strong investor interest [1] Group 2 - The medical device ETF (159873) also reached new highs in scale and shares as of January 13, with a net inflow of 26.503 million yuan over the past four days, leading its category with a net flow rate of 28.22% [2] - The medical device ETF has a high concentration in brain-computer interface stocks, accounting for over 19%, and is expected to benefit from domestic innovation, accelerated exports, and new technologies [2] - WuXi AppTec's stock price reached a new high, with a projected revenue of 45.456 billion yuan for 2025, reflecting a year-on-year growth of 15.84% [3][4] Group 3 - WuXi AppTec's adjusted net profit is expected to be 14.957 billion yuan for 2025, a year-on-year increase of 41.33%, driven by its focus on a unique "integrated, end-to-end" CRDMO business model [3] - The company is expected to maintain strong performance in 2026, supported by a solid business foundation and a clear strategic path [4] - The biopharmaceutical industry is anticipated to face external uncertainties, but WuXi AppTec's comprehensive service capabilities and enhanced quality systems are seen as valuable certainties in the market [4]

Core Viewpoint - Jingtai Holdings (02228) has seen a significant increase in stock price, rising over 4% today and nearly 50% in the month, driven by positive developments in its subsidiary ReviR's drug pipeline RTX-117 [1] Group 1: Company Developments - Jingtai Technology announced that its incubated company ReviR has achieved a milestone with the successful dual approval of RTX-117 in both the US and China [1] - ReviR will continue the clinical development of RTX-117, and Jingtai Technology is entitled to participate in sales revenue sharing and future licensing income from this pipeline [1] Group 2: Market Analysis - Guolian Minsheng Securities published a report stating that Jingtai Holdings has established a competitive moat in the AI pharmaceutical sector through its software and hardware technology accumulation and platform-based business model [1] - The clinical approval of RTX-117 marks the beginning of the value realization phase for its technology platform, with significant potential for performance elasticity and valuation restructuring as the collaboration pipeline expands [1]

Core Viewpoint - The company BaiO Saite-B (02315) has seen a significant stock increase of over 12%, with a cumulative rise of approximately 30% over the past three days, indicating strong market interest and confidence in its recent developments [1] Group 1: AI-Driven Antibody Drug Development - The company has completed the localization deployment of its AI-driven antibody drug development platform, which is expected to enhance collaboration with its core business, the "Thousand Mice and Ten Thousand Antibodies" initiative [1] - The integration of AI into the antibody drug development process aims to provide global pharmaceutical companies with more efficient research tools and a richer antibody molecule library, thereby improving the efficiency of preclinical PCC molecule development [1] Group 2: Strategic Partnerships - The company has entered into a licensing agreement with Yushibo to systematically evaluate the BsADC (bispecific antibody-drug conjugate) project through a structured assessment mechanism, which is intended to accelerate the development of BsAD2C (bispecific antibody dual-drug conjugate) [1]

Core Viewpoint - Jingtai Holdings (02228) has seen a significant increase in stock price, rising over 4% today and nearly 50% for the month, driven by positive developments in its subsidiary ReviR's innovative drug pipeline RTX-117 [1] Group 1: Company Developments - Jingtai Technology announced that its incubated company ReviR has achieved a milestone with the successful dual approval of RTX-117 in both China and the U.S. [1] - ReviR will pay Jingtai a milestone payment totaling tens of millions of Hong Kong dollars as part of this achievement [1] - Jingtai has the right to participate in revenue sharing from the sales and subsequent licensing of the RTX-117 pipeline [1] Group 2: Market Analysis - Guolian Minsheng Securities published a report stating that Jingtai Holdings has established a competitive moat in the AI pharmaceutical sector through its software and hardware technology accumulation, platform-based business model, and strategic positioning [1] - The clinical approval of RTX-117 marks the beginning of the value realization phase for Jingtai's technology platform, with significant potential for performance elasticity and valuation reconfiguration as the collaboration pipeline continues to expand [1]

Core Insights - The medical device ETF (159873) has shown strong trading activity with a turnover of 26.84% and a transaction volume of 36.34 million yuan, while the underlying index, the CSI All Share Healthcare Equipment and Services Index (H30178), increased by 1.09% [1] - The innovative drug ETF Tianhong (517380) also performed well, with a turnover of 5.36% and a transaction volume of 95.97 million yuan, tracking the Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drug Select 50 Index (HSSSHID), which rose by 2.21% [1] - Both ETFs reached new highs in terms of scale and shares as of January 13, 2026, with the medical device ETF achieving a record scale and share, while the innovative drug ETF reached a scale of 1.807 billion yuan and 2.162 billion shares [2][3] Fund Flows - The medical device ETF (159873) has seen a net inflow of 26.50 million yuan over the past four days [1] - The innovative drug ETF Tianhong (517380) experienced a net inflow of 264 million yuan over the last six days [3] Product Highlights - The medical device ETF (159873) has a high concentration in brain-computer interface technology, accounting for over 19%, with nearly 80% of its components from the Sci-Tech Innovation Board and the Growth Enterprise Market [4] - The innovative drug ETF Tianhong (517380) targets opportunities in the innovative drug sector, benefiting from the concentration of top component stocks like WuXi AppTec and Hengrui Medicine, alongside the growth in BD transactions and breakthroughs in AI drug development [4] Industry Events - Qiangnao Technology, a brain-computer interface company, has submitted a confidential IPO application for listing on the Hong Kong Stock Exchange, potentially becoming the first listed company in China's brain-computer interface sector [4] - The company has completed approximately 2 billion yuan in financing, marking the second-largest financing event globally in the brain-computer interface field, excluding Neuralink [4][5] Institutional Perspectives - Analysts from Changcheng Guorui Securities view brain-computer interfaces as a forward-looking direction under the 14th Five-Year Plan, with several recommended industry standards being established to promote technological standardization and clinical registration processes [5]

Core Viewpoint - The announcement of RTX-117's clinical trial approval marks a significant milestone for Jingtai Technology and its collaboration with ReviR, showcasing the potential of AI and robotics in drug development for rare diseases [1][3]. Group 1: Clinical Development - RTX-117, a small molecule drug targeting Charcot-Marie-Tooth disease (CMT), has received clinical trial approval from the National Medical Products Administration, with plans to initiate Phase I trials in Q1 2026 [1]. - This drug is the first of its kind in China for CMT and represents the first clinical project from a series of rare disease drug pipelines developed through AI and robotic assistance [1]. Group 2: Technology and Business Model - The company has established a closed-loop model integrating quantum physics, AI, and robotics, enabling faster and more reliable drug development [2]. - The technology leverages first-principles calculations to simulate atomic and electronic interactions, generating high-precision virtual data even with limited training data [2]. - The company has developed over 200 AI vertical models, creating a robust algorithm engine, and has built a leading automated experimental platform for high-quality, high-throughput research data generation [2]. Group 3: Market Position and Financial Outlook - The company has formed long-term partnerships with 17 of the top 20 global pharmaceutical companies, validating the reliability and universality of its technology platform [3]. - In 2025, the company secured a pipeline collaboration worth nearly $6 billion with DoveTree, and reported a 404% year-on-year revenue growth in the first half of 2025, achieving profitability for the first time [3]. - Revenue projections for 2025-2027 are estimated at 785 million, 1.087 billion, and 1.485 billion yuan, reflecting year-on-year growth rates of 194.5%, 38.5%, and 36.6% respectively [3].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 12 months [2]. Core Insights - The company has entered a value realization phase with its AI pharmaceutical platform, highlighted by the clinical trial approval of its drug RTX-117 for Charcot-Marie-Tooth disease, marking a significant milestone in its drug development pipeline [6]. - The innovative approach of RTX-117 targets the key mechanisms of the disease, demonstrating effective restoration of motor function in preclinical studies, thus validating the company's AI-driven drug development capabilities [6]. - The company has established a robust business model that integrates AI technology with a flexible commercial strategy, allowing for rapid drug development and a diversified revenue stream from collaborations with major pharmaceutical companies [6]. - The financial projections indicate substantial revenue growth, with expected revenues of RMB 785 million in 2025 and RMB 1.485 billion in 2027, alongside a path to profitability by 2027 [2][7]. Financial Projections - Revenue is projected to grow from RMB 266 million in 2024 to RMB 1.485 billion in 2027, reflecting a compound annual growth rate (CAGR) of approximately 36.6% [2][7]. - The net profit attributable to shareholders is expected to improve from a loss of RMB 1.517 billion in 2024 to a profit of RMB 92 million in 2027, indicating a significant turnaround [2][7]. - The earnings per share (EPS) is forecasted to transition from -0.35 RMB in 2024 to 0.02 RMB in 2027, suggesting a positive shift towards profitability [2][7].

主线热点 2026年1月12日凌晨，谷歌宣布与沃尔玛、塔吉特、Wayfair、Etsy等全球头部零售商达成合作，并正式 开源面向电商领域的AI智能体协议通用商业协议。隔夜美股中概股集体走强，阿里巴巴大涨10%。此前 受到马斯克宣布在7天内开源X最新一代推荐算法提振的AI应用端延续强势，GEO概念天龙集团、引力 传媒、利欧股份、三维通信实现连板晋级，不过20厘米中军蓝色光标放量巨震，仍受到其进入重点监控 名单影响，拖累弹性方向人气股流金科技、易点天下、值得买等纷纷炸板回落。整个应用端连板高度和 连板股家数的显著减少，对于弹性方向的赚钱效应压制明显。不过随着今日分歧的率先释放，若市场短 线情绪能够企稳，不排除20厘米方向部分个股存在反包修复可能。 英伟达宣布，将在未来五年内与礼来共同投资10亿美元建立人工智能药物实验室。AI医疗、AI制药概 念受此消息刺激双双爆发，泓博医药、美年健康一字涨停，带动思创医惠、诺思格、博济医药、贝瑞基 因等多股涨停。综合多券商研报观点，AI制药核心价值在于大幅提升药物早研效率，候选药物从靶点 发现到临床前候选药物确认时间有望显著缩短三分之二以上，因此一些主营聚焦于临床前试验的CXO ...